Search the Newsreel

SELLAS Life Sciences Group, Inc. (SLS) stock price, news, quote and history

SELLAS Life Sciences Group, Inc. (SLS) stock price increased by 6.15%, trading at 11.73 USD. The company is a late-stage clinical biopharmaceutical firm developing novel cancer therapeutics, with lead candidates including galinpepimut-S (GPS) and SLS009 (tambiciclib). SELLAS has strategic collaborations with Merck & Co., …

SELLAS Life Sciences Group, Inc. $SLS is Dagco Inc.'s 10th Largest Position

Dagco Inc. has significantly increased its stake in SELLAS Life Sciences Group (NASDAQ:SLS), making it their 10th largest position. Despite this institutional confidence, analyst ratings are mixed, leading to a consensus "Hold" rating, and the company recently missed its quarterly earnings estimates.

Earnings Flash (SLS) SELLAS Life Sciences Posts Q2 Loss $0.05, vs. FactSet Est of $0.05 Loss

SELLAS Life Sciences Group (NASDAQ:SLS) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

SELLAS Life Sciences Group (NASDAQ:SLS) announced its quarterly earnings, reporting a loss of $0.05 per share, missing analyst expectations by $0.01. Despite the earnings miss, SLS shares rose 0.1% to $11.05, with a mixed analyst sentiment leading to an overall "Hold" rating and a …

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SELLAS Life Sciences Group, Inc. reported its second-quarter 2026 financial results, highlighting progress in its lead clinical programs, GPS and SLS009. The company is nearing the final efficacy analysis for the Phase 3 REGAL trial of GPS in AML and expects topline data for …

Sellas Life Sciences reports wider loss as REGAL trial nears final analysis (SLS:NASDAQ)

SELLAS Life Sciences Group, Inc. Q2 2026: Revenue $0 Net loss $(9.6M), EPS $(0.05) — 10-Q Summary

SELLAS Life Sciences Group, Inc. reported its second-quarter 2026 results, showing no revenue and a net loss of $(9.6M), or $(0.05) diluted loss per share. This represents a worsening net loss compared to the $(6.6M) in the prior-year quarter, though diluted EPS improved from …

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 6.8% - What's Next?

Solstice Minerals (ASX:SLS) Eases Back After Strong Exploration Run

Sellas Life Sciences Group Stock (SLS) Opinions on Institutional Buying Surge

The article discusses the recent surge in institutional buying of Sellas Life Sciences Group (SLS) stock, noting a significant increase in the number of funds and shares held by institutions. Despite this, the stock's price performance has been negative over various periods, underperforming the …

State Street Corporation (SLS) discloses 7% ownership of SELLAS Life Sciences common stock

State Street Corporation and its investment adviser subsidiaries have reported a 7% passive ownership stake in SELLAS Life Sciences Group Inc., as detailed in a Schedule 13G filing. As of June 30, 2026, they beneficially owned 12,996,558 shares, exercising shared voting and dispositive power …

Sellas Life Sciences may see 12% move on Aug. 13 earnings

Sellas Life Sciences Group Inc. is projected to experience a 12% stock movement when it reports earnings on August 13, according to options data. This prediction, derived from options trading, has accurately indicated the direction of stock price movements in six out of its …

Solaris Resources Files Q2 2026 Interim Results, Assets Rise but Shareholders’ Deficit Widens

Solaris Resources Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

SELLAS Life Sciences Group, Inc. (RXK3.F) Stock Price, News, Quote & History

This article provides detailed financial information, news, and historical data for SELLAS Life Sciences Group, Inc. (RXK3.F). It covers the company's stock performance, key financial metrics, an overview of its biopharmaceutical operations, and recent clinical development collaborations. The data highlights significant stock returns over …

SELLAS Life Sciences Group (SLS) Is Up 11.2% After Daiwa Boosts Stake And REGAL Nears Readout - Has The Bull Case Changed?

SELLAS Life Sciences Group (SLS) shares rose 11.2% following Daiwa Securities' increased stake and the imminent readout of the Phase 3 REGAL trial for acute myeloid leukemia. With 78 out of 80 events reached for final analysis and a strong cash position of US$138.30 …

SELLAS Life Sciences Group (SLS) Nears REGAL Analysis, Is The Stock Too Expensive?

SELLAS Life Sciences Group (SLS) is approaching the final analysis of its Phase 3 REGAL trial for acute myeloid leukemia, coinciding with a significant increase in shareholding by Daiwa Securities. Despite a recent surge in stock price, including a 157.93% year-to-date return, the company's …

SELLAS Life Sciences Group (SLS) Stock Looks Priced At A Premium

SLS Stock Climbs Premarket: Here’s What Smart Money Is Doing As Sellas Nears Critical Phase 3 AML Readout

Sellas Life Sciences (SLS) stock saw premarket gains as investors reacted to mixed institutional stake disclosures and the company's nearing Phase 3 clinical trial readout for its AML drug. CEO Angelos Stergiou highlighted the role of AI in drug development and patient selection, while …

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 12.4% Higher - Time to Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) saw its shares rise by 12.4% on Monday, trading at $11.25 with 4.46 million shares exchanged, which is 47% below its average daily volume. Analyst sentiment is mixed, with a "Hold" consensus and an average price target of $10.00. …

SELLAS Life Sciences Group Stock (SLS) Opinions on Clinical Trial Catalysts

Social media discussions highlight an anticipated surge in SELLAS Life Sciences Group (SLS) stock due to upcoming clinical data releases and potential acquisition rumors. Analysts suggest price targets of $25 to $30 in a successful trial scenario, with market sentiment shifting to cautiously positive …

SELLAS Life Sciences Group (SLS) Expected to Release Quarterly Earnings on Thursday

SLS Stock In Spotlight After Vanguard Capital Discloses 5.19% Stake – Retail Calls It ‘Huge Vote Of Conviction’ As AML Trial Readout Nears

Vanguard Capital Management has disclosed a 5.19% stake in Sellas Life Sciences Group (SLS), holding 9.67 million shares as of June 30, 2026. This comes as several other institutional investors also increased their positions in the company, with retail investors viewing Vanguard's move as …

Vanguard Capital Management (SLS) discloses 5.19% warrant-based stake in SELLAS

Vanguard Capital Management has filed a Schedule 13G, disclosing a beneficial ownership of 5.19% in SELLAS Life Sciences Group Inc, amounting to 9,666,278 securities as of June 30, 2026. The stake is primarily in the form of warrants, with Vanguard reporting sole voting power …

SELLAS Life Sciences Group (SLS) Nears REGAL Readout As Valuation Questions Return

Solstice Minerals (ASX:SLS) Extends Nanadie Copper-Gold System at Depth as Assays Roll In

Sellas Life Sciences Group Inc (SLS) Institutional Confidence

Sellas Life Sciences Group Inc (SLS) has an institutional shareholding score of 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The company's institutional shareholding proportion is 26.02%, showing a 25.11% quarter-over-quarter increase. While the largest institutional shareholder, Bill …

Solstice Minerals (ASX:SLS) Retreats Amid Exploration Sector Weakness

SLS|Sellas Life Sciences Group Inc|Price:9.810|Chg%:-1.025

TradingKey provides a comprehensive stock analysis of Sellas Life Sciences Group Inc (SLS), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company's stock has high institutional ownership and analysts rate it as "Buy" …

SELLAS Life Sciences (NASDAQ:SLS) drops as new share count suggests $2.14 billion market cap

SELLAS Life Sciences (NASDAQ:SLS) shares dropped by 3.9% on Monday, following an 8.3% decline on Friday, despite the broader biotechnology sector seeing gains. The decrease is partly attributed to a new share count revealing a provisional equity value of $2.14 billion, a 14% premium …

3D Medicines prevails in arbitration against Sellas, awarded $1M in costs (SLS:NASDAQ)

3D Medicines has won an arbitration case against Sellas Life Sciences Group, with the arbitrator dismissing all of Sellas's claims. Sellas has been ordered to reimburse 3D Medicines nearly HK$8 million (approximately $1.02 million) in legal costs.

SLS Stock Whipsaws As Social Buzz Collides With Weak Fundamentals

SELLAS Life Sciences Group Inc. (SLS) stock recently experienced significant volatility, trading down by -6.84% due to bearish sentiment around its oncology pipeline, following a sharp 18% surge and a 7% premarket gain the previous week. This whipsaw action is attributed more to WallStreetBets-style …

Sellas Life Sciences Stock (SLS) Opinions on REGAL Trial Catalysts

Sellas Life Sciences (SLS) stock opinions are centered around the upcoming REGAL trial readout. Investors are looking for a clear path to approval based on these results.